Internalization by multiple endocytic pathways and lysosomal processing impact maspin-based therapeutics.

ABSTRACT:

Unlabelled

Patients with metastatic disease face high rates of mortality with a paucity of therapeutic options. Protein-based therapeutics provide advantages over traditional chemotherapy through increased specificity, decreased immune impairment, and more direct means of delivery. However, development is often hindered because of insufficient knowledge about protein processing by cells when exogenously applied. This study focuses on recombinant Maspin (rMaspin), a serine protease inhibitor (SERPINB5), which alters invasive properties when directly applied to cancer cells. Previous evidence suggests differences in the effects of rMaspin treatment when compared with endogenous reexpression, with little explanation for these discrepancies. A leading hypothesis is that exogenously app

SUBMITTER: Bodenstine TM 

PROVIDER: S-EPMC4201961 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature